The WHO classification was used to indicate the incidence of adverse events: very frequent (≥10 %); frequent (≥1% and <10%); infrequent (≥0.1% and <1%); rare (≥0.01% and <0.1%); very rare (<0.01%); an unknown frequency (according to available data, it is not possible to determine the frequency of occurrence of a side effect).
From the digestive system: often - diarrhea or constipation, abdominal pain, nausea, vomiting, flatulence; rarely - increased activity of "liver" enzymes, taste disorders, microscopic colitis, dry mouth, stomatitis, in patients with a previous severe liver disease - hepatitis (including jaundice), a violation of liver function.
On the part of the organs of hematopoiesis: rarely - leukopenia, thrombocytopenia, hypochromic microcytic anemia in children; very rarely - agranulocytosis, pancytopenia.
From the nervous system: in patients with severe concomitant somatic diseases often - headache, infrequently - dizziness, insomnia, vertigo,rarely - agitation, depression, paresthesia, hallucinations; It is very rare in patients with a previous severe liver disease - encephalopathy.
From the side of the musculoskeletal system: infrequently - fractures of the hip, bones of the wrist and vertebrae; rarely - arthralgia, myasthenia gravis, myalgia.
From the skin: infrequently - hives, skin rash, itching, rarely - photosensitivity, very rarely - alopecia, multiforme exudative erythema, Stevens-Johnson syndrome, toxic epidermal necrolysis.
From the immune system: rarely - anaphylactic reactions / anaphylactic shock, angioedema, fever.
Disorders from the kidneys and urinary tract: rarely interstitial nephritis.
Disturbances from the respiratory system, chest and mediastinal organs: rarely - bronchospasm.
Other: rarely - gynecomastia, malaise, visual impairment, peripheral edema, increased sweating, the formation of gastric glandular cysts during long-term treatment (consequence of inhibition of HCI, is benign, reversible), hypomagnesemia, hyponatremia.